Lenalidomide versus Thalidomide or Bortezomib as maintenance regimen for non-transplant patients with multiple myeloma: multi-center real world experiences in China

被引：0

作者：

Zhuang, Zhe ^{[1
]}

Shi, Lei ^{[2
]}

Tian, Ying ^{[3
]}

Zou, Dongmei ^{[4
]}

Feng, Ru ^{[5
]}

Dong, Fei ^{[6
]}

Ma, Yanping ^{[7
]}

Yu, Hong ^{[8
]}

Tian, Wei-wei ^{[9
]}

Liu, Shuangjiao ^{[1
]}

Ma, Liang-Ming ^{[10
]}

Fu, Rong ^{[8
]}

Jing, Hongmei ^{[6
]}

Liu, Hui

Sun, Wanling ^{[4
]}

Chen, Wenming ^{[3
]}

Wu, Yin ^{[3
]}

Bao, Li ^{[2
]}

Zhuang, Junling ^{[1
]}

机构：

[1] Chinese Acad Med Sci, Dept Hematol, Peking Union Med Coll Hosp, Beijing, Peoples R China

[2] Beijing Jishuitan Hosp, Dept Hematol, Beijing, Peoples R China

[3] Capital Med Univ, Dept Hematol, Beijing Chao Yang Hosp, Beijing, Peoples R China

[4] Capital Med Univ, Dept Hematol, Xuanwu Hosp, Beijing, Peoples R China

[5] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Dept Hematol, Beijing, Peoples R China

[6] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China

[7] Shanxi Med Univ, Dept Hematol, Hosp 2, Taiyuan, Peoples R China

[8] Tianjin Med Univ, Dept Hematol, Gen Hosp, Tianjin, Peoples R China

[9] Shanxi Med Univ, Dept Hematol, Shanxi Bethune Hosp, Taiyuan, Peoples R China

[10] Shanxi Med Univ, Hosp 2, Dept Hematol, Taiyuan, Peoples R China

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-141

引用

页码：S112 / S113

页数：2

共 50 条

[31] Results of a multi-center randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma following autologous stem cell transplant.
Stewart, AK
Chen, C
Howson-Jan, K
White, D
Roy, J
Kovacs, MJ
Shustik, C
Sadura, A
Lois, S
Ding, K
Meyer, RM
Belch, A
BLOOD, 2004, 104 (11) : 99A - 99A
[32] Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.
Ishida, Tadao
Kimura, Hideo
Kubo, Koumei
Sunami, Kazutaka
Ozaki, Shuji
Takezako, Naoki
Handa, Hiroshi
Kosugi, Hiroshi
Murakami, Hirokazu
Shimizu, Kazuyuki
BLOOD, 2015, 126 (23)
[33] Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand
Pimjai Niparuck
Ladda Sorakhunpipitkul
Vichai Atichartakarn
Suporn Chuncharunee
Artit Ungkanont
Pantep Aungchaisuksiri
Teeraya Puavilai
Saengsuree Jootar
Journal of Hematology & Oncology, 3
[34] Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand
Niparuck, Pimjai
Sorakhunpipitkul, Ladda
Atichartakarn, Vichai
Chuncharunee, Suporn
Ungkanont, Artit
Aungchaisuksiri, Pantep
Puavilai, Teeraya
Jootar, Saengsuree
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
[35] Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma
Bumma, Naresh
Dhakal, Binod
Fraser, Raphael
Estrada-Merly, Noel
Anderson, Kenneth
Freytes, Cesar O.
Hildebrandt, Gerhard C.
Holmberg, Leona
Krem, Maxwell M.
Lee, Cindy
Lekakis, Lazaros
Lazarus, Hillard M.
Mian, Hira
Murthy, Hemant S.
Nathan, Sunita
Nishihori, Taiga
Parrondo, Ricardo
Patel, Sagar S.
Solh, Melhem
Strouse, Christopher
Vesole, David H.
Kumar, Shaji
Qazilbash, Muzaffar H.
Shah, Nina
D'Souza, Anita
Sidana, Surbhi
CANCER, 2023, 129 (14) : 2179 - 2191
[36] Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma
Gasparet, Cristina
Gockerman, Jon P.
Diehl, Louis F.
De Castro, Carlos, III
Moore, Joseph
Long, Gwynn D.
Horwitz, Mitchell
Chute, John
Sullivan, Keith M.
Netuwirth, Rachel
Davis, Patricia H.
Sutton, Linda M.
Anderson, Russell D.
Chao, Nelson
Rizzieri, David A.
BLOOD, 2008, 112 (11) : 1142 - 1142
[37] Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project
Franchi, Matteo
Vener, Claudia
Garau, Donatella
Kirchmayer, Ursula
Di Martino, Mirko
Romero, Marilena
De Carlo, Ilenia
Scondotto, Salvatore
Stival, Chiara
Della Porta, Matteo Giovanni
Passamonti, Francesco
Corrao, Giovanni
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
[38] First-line therapy with Bendamustine/Prednisone/Bortezomib (BPV) for non-transplant eligible symptomatic multiple myeloma patients
Knauf, W.
Dingeldein, G.
Schlag, R.
Welslau, M.
Kunz, C.
Moehler, T.
Habermehl, C.
Goldschmidt, H.
Raab, M-S
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 188 - 188
[39] Lenalidomide maintenance in R2-ISS stratified multiple myeloma patients - real world evidence
Radocha, Jakub
Jungova, Alexandra
Pour, Ludek
Spicka, Ivan
Minarik, Jiri
Jelinek, Tomas
Jindra, Pavel
Stork, Martin
Pika, Tomas
Sedlak, Frantisek
Popkova, Tereza
Novakova, Denisa
Sykora, Michal
Pavlicek, Petr
Heindorfer, Adriana
Wrobel, Marek
Gregora, Evzen
Mikula, Peter
Obernauerova, Jarmila
Ullrychova, Jana
Stejskal, Lukas
Kessler, Petr
Maisnar, Vladimir
Hajek, Roman
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S122 - S123
[40] Real world health and economic outcomes in patients with non-stem cell transplant (NSCT) multiple myeloma initially treated with lenalidomide and/or bortezomib-based regimens.
Parikh, Kejal
Abouzaid, Safiya
Chen, Chi-Chang
McGuiness, Catherine Balderston
Wade, Rolin L.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →